×
About 19,133 results

ALLMedicine™ Hodgkin Lymphoma Center

Research & Reviews  6,260 results

New Directions for Mantle Cell Lymphoma in 2022.
https://doi.org/10.1200/EDBK_349509
American Society of Clinical Oncology Educational Book. A... Kumar A, Eyre TA et. al.

May 14th, 2022 - Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the most powerful prognostic indices is the Mantle Cell Lymphoma Interna...

Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in agg...
https://doi.org/10.1080/10428194.2022.2068007
Leukemia & Lymphoma; Gordon MJ, Sureda A et. al.

May 14th, 2022 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma. Combination chemotherapy with immunotherapy can be curative, however, nearly one-third of patients will have a disease that is refractory or will rel...

Long-term exposure to wildfires and cancer incidence in Canada: a population-based obse...
https://doi.org/10.1016/S2542-5196(22)00067-5
The Lancet. Planetary Health; Korsiak J, Pinault L et. al.

May 14th, 2022 - Wildfires emit many carcinogenic pollutants that contaminate air, water, terrestrial, and indoor environments. However, little is known about the relationship between exposure to wildfires and cancer risk. We aimed to assess the associations betwe...

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03739827

May 13th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...

see more →

Guidelines  17 results

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, A...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723685
Journal of Clinical Oncology : Official Journal of the Am... Mulder RL, Hudson MM et. al.

Oct 21st, 2020 - As new evidence is available, the International Late Effects of Childhood Cancer Guideline Harmonization Group has updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer. We used ev...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow...
https://doi.org/10.1093/annonc/mdy080
Annals of Oncology : Official Journal of the European Soc... Eichenauer DA, Aleman BMP et. al.

Oct 1st, 2018 - Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2018|Eichenauer DA,Aleman BMP,André M,Federico M,Hutchings M,|diagnosis,epidemiology,therapy,standards,

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in ...
https://doi.org/10.6004/jnccn.2018.0066
Journal of the National Comprehensive Cancer Network : JN... Reid E, Suneja G et. al.

Aug 14th, 2018 - People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment ...

see more →

Drugs  63 results see all →

Clinicaltrials.gov  298 results

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03739827

May 13th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
https://clinicaltrials.gov/ct2/show/NCT00967785

May 13th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03907488

May 13th, 2022 - PRIMARY OBJECTIVE: I. To compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin hydrochloride [doxorubicin], vinblastine sulfate [vinblasti...

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03479268

May 13th, 2022 - PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of pevonedistat administered in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). SECONDARY OBJECTIV...

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04739813

May 13th, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas an...

see more →

News  1,013 results

Ublituximab/Umbralisib BLA/sNDA in CLL and SLL Voluntarily Withdrawn
https://www.onclive.com/view/ublituximab-umbralisib-bla-snda-in-cll-and-sll-voluntarily-withdrawn

May 6th, 2022 - The pending biologics license application (BLA) and supplemental new drug application (sNDA) seeking the approval of the combination of ublituximab and umbralisib (Ukoniq; U2) in adult patients with chronic lymphocytic leukemia (CLL) and small lym...

'Unprecedented Crisis': Dacarbazine Shortage Prompts Search for Substitute Hodgkin Therapy
https://www.medscape.com/viewarticle/973396

May 4th, 2022 - The persistent shortage of dacarbazine has led to an "acute and unprecedented crisis" in the treatment of patients with advanced classical Hodgkin lymphoma, experts say. Dacarbazine, an essential part of the four-drug standard of care for managing...

Dr. Westin on the Evolving Landscape of CAR T-Cell Therapy in NHL
https://www.onclive.com/view/dr-westin-on-the-evolving-landscape-of-car-t-cell-therapy-in-nhl

May 3rd, 2022 - Jason R. Westin, MD, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolv...

Hodgkin Lymphoma Clinical Practice Guidelines (NCCN, 2022)
https://www.medscape.com/viewarticle/972832

Apr 29th, 2022 - Guidelines for the management of Hodgkin lymphoma were published in April 2022 by the National Comprehensive Cancer Network (NCCN) in Journal of the National Comprehensive Cancer Network (JNCCN).[1] Radiation therapy (RT) delivery techniques that ...

Dr. Bezerra on Barriers to Enrollment for Clinical Trials in B-Cell NHL
https://www.onclive.com/view/dr-bezerra-on-barriers-to-enrollment-for-clinical-trials-in-b-cell-nhl

Apr 26th, 2022 - Evandro D. Bezerra, MD, clinical fellow of Hematology, Mayo Clinic, discusses barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have progressed on anti-CD19 CAR T-cell therapy. This patie...

see more →

Patient Education  2 results see all →